Entropy Technologies LP Has $1.65 Million Stake in Teladoc Health, Inc. (NYSE:TDOC)

Entropy Technologies LP cut its position in Teladoc Health, Inc. (NYSE:TDOC) by 25.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 179,537 shares of the health services provider’s stock after selling 61,883 shares during the quarter. Entropy Technologies LP owned 0.10% of Teladoc Health worth $1,648,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Signaturefd LLC lifted its stake in Teladoc Health by 148.7% during the second quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock worth $28,000 after purchasing an additional 1,715 shares during the last quarter. International Assets Investment Management LLC acquired a new stake in Teladoc Health in the second quarter valued at about $29,000. SageView Advisory Group LLC bought a new position in Teladoc Health in the first quarter valued at about $48,000. Covestor Ltd raised its stake in Teladoc Health by 58.1% during the first quarter. Covestor Ltd now owns 3,817 shares of the health services provider’s stock worth $57,000 after acquiring an additional 1,403 shares in the last quarter. Finally, Blue Trust Inc. lifted its holdings in shares of Teladoc Health by 84.5% in the third quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider’s stock worth $40,000 after acquiring an additional 1,854 shares during the last quarter. Institutional investors own 76.82% of the company’s stock.

Insider Activity at Teladoc Health

In related news, Director Thomas Mckinley purchased 4,000 shares of Teladoc Health stock in a transaction on Thursday, September 12th. The stock was acquired at an average cost of $7.69 per share, for a total transaction of $30,760.00. Following the completion of the acquisition, the director now owns 39,077 shares of the company’s stock, valued at $300,502.13. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Thomas Mckinley acquired 4,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were bought at an average price of $7.69 per share, with a total value of $30,760.00. Following the transaction, the director now directly owns 39,077 shares of the company’s stock, valued at $300,502.13. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Michael Willem Waters sold 4,218 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total value of $30,200.88. Following the completion of the sale, the chief operating officer now directly owns 78,309 shares of the company’s stock, valued at $560,692.44. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 20,051 shares of company stock worth $143,565 in the last quarter. Company insiders own 0.95% of the company’s stock.

Teladoc Health Trading Down 1.1 %

Shares of TDOC opened at $9.71 on Wednesday. The company has a quick ratio of 1.69, a current ratio of 1.73 and a debt-to-equity ratio of 0.66. The firm’s fifty day simple moving average is $8.79 and its two-hundred day simple moving average is $9.44. Teladoc Health, Inc. has a 12 month low of $6.76 and a 12 month high of $22.54.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.10. Teladoc Health had a negative return on equity of 10.06% and a negative net margin of 37.91%. The business had revenue of $640.51 million during the quarter, compared to analysts’ expectations of $630.50 million. Equities analysts expect that Teladoc Health, Inc. will post -1.19 earnings per share for the current year.

Analysts Set New Price Targets

TDOC has been the topic of several research reports. Evercore ISI lifted their price target on shares of Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a report on Tuesday, October 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $10.00 price target on shares of Teladoc Health in a report on Tuesday, August 20th. Piper Sandler cut their price objective on Teladoc Health from $25.00 to $10.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Oppenheimer lowered their target price on Teladoc Health from $21.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. Finally, Truist Financial cut their price target on Teladoc Health from $15.00 to $10.00 and set a “hold” rating on the stock in a research note on Friday, August 2nd. Fourteen investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $11.97.

Teladoc Health Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.